Subcutaneous Benlysta belimumab: Phase III data

The double-blind, international Phase III BLISS-SC trial in 836 patients with active, autoantibody-positive SLE showed that once-weekly 200 mg subcutaneous Benlysta plus standard of care (SOC) met the...